Sinopharm Group Co Ltd Class H (HK:1099)
:1099
Want to see HK:1099 full AI Analyst Report?
Top Page
Sinopharm Group Co
(1099)
Select Model
Select Model
Rating:57Neutral
Price Target:
HK$20.00
▼(-1.38% Downside)
Action:DowngradedDate:04/25/26
The score is held back mainly by weak recent financial momentum (margin compression, slight revenue contraction, rising leverage) and bearish technical signals (below major moving averages with negative MACD). These risks are partially offset by an attractive valuation (low P/E) and a supportive dividend yield.
Positive Factors
Scale & Distribution Network
Sinopharm's nationwide distribution, retail pharmacy and logistics footprint creates durable scale advantages. Large purchasing volumes and entrenched manufacturer and hospital relationships generate recurring volume, pricing leverage and high switching costs that defend market position.
Negative Factors
Rising Leverage
Debt/equity rising to ~1.29x increases financial leverage and interest burden. Higher indebtedness reduces financial flexibility, raises refinancing and cost-of-capital risk, and constrains capital allocation for growth, M&A or buffers during sector slowdowns.
Read all positive and negative factors
Positive Factors
Negative Factors
Scale & Distribution Network
Sinopharm's nationwide distribution, retail pharmacy and logistics footprint creates durable scale advantages. Large purchasing volumes and entrenched manufacturer and hospital relationships generate recurring volume, pricing leverage and high switching costs that defend market position.
Read all positive factors
Sinopharm Group Co (1099) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$58.61B
Dividend Yield3.75%
Average Volume (3M)4.67M
Price to Earnings (P/E)7.8
Beta (1Y)0.72
Revenue Growth-1.57%
EPS Growth1.55%
CountryHK
Employees108,217
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.52
Shares Outstanding1,341,810,800
10 Day Avg. Volume3,523,930
30 Day Avg. Volume4,674,378
Financial Highlights & Ratios
PEG Ratio-8.83
Price to Book (P/B)0.65
Price to Sales (P/S)0.10
P/FCF Ratio4.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.32Price Target Upside15.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)2.44
Revenue Forecast (FY)HK$594.16B
Sinopharm Group Co Business Overview & Revenue Model
Company Description
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutic...
How the Company Makes Money
Sinopharm primarily makes money by selling pharmaceuticals and healthcare products through large-scale distribution networks. Its core revenue stream is pharmaceutical distribution: it procures prescription drugs, over-the-counter medicines, and o...
Sinopharm Group Co Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
60
Neutral
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 560.28B | 584.51B | 596.57B | 552.15B | 521.05B |
| Gross Profit | 40.15B | 44.26B | 48.51B | 47.43B | 44.05B |
| EBITDA | 20.41B | 20.17B | 26.90B | 26.25B | 24.68B |
| Net Income | 6.97B | 7.05B | 9.05B | 8.53B | 7.76B |
Balance Sheet | |||||
| Total Assets | 390.53B | 392.83B | 383.39B | 364.78B | 335.41B |
| Cash, Cash Equivalents and Short-Term Investments | 61.59B | 54.31B | 63.81B | 55.22B | 43.54B |
| Total Debt | 108.63B | 76.39B | 73.78B | 69.59B | 68.37B |
| Total Liabilities | 256.31B | 266.14B | 263.08B | 254.71B | 235.76B |
| Stockholders Equity | 83.99B | 78.88B | 74.58B | 68.07B | 61.89B |
Cash Flow | |||||
| Free Cash Flow | 12.52B | 9.58B | 14.84B | 18.55B | 7.05B |
| Operating Cash Flow | 14.14B | 11.55B | 17.17B | 20.96B | 9.31B |
| Investing Cash Flow | -963.89M | -3.75B | -944.53M | -3.59B | -1.27B |
| Financing Cash Flow | -18.69B | -17.29B | -7.64B | -5.69B | -14.69B |
Sinopharm Group Co Technical Analysis
Negative
20.28
Price Trends
20.91
Negative
20.59
Negative
19.81
Positive
Market Momentum
-0.06
Negative
44.83
Neutral
27.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1099, the sentiment is Negative. The current price of 20.28 is below the 20-day moving average (MA) of 20.58, below the 50-day MA of 20.91, and above the 200-day MA of 19.81, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.83 is Neutral, neither overbought nor oversold. The STOCH value of 27.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1099.
Sinopharm Group Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$6.41B | 19.61 | 6.83% | 2.72% | 15.04% | 5.57% | |
67 Neutral | HK$64.91B | 6.62 | 7.64% | 2.67% | 3.11% | 25.08% | |
66 Neutral | HK$1.52B | -231.76 | 4.85% | 3.81% | -10.71% | -87.93% | |
60 Neutral | HK$628.56M | 7.33 | 7.59% | 8.03% | -1.09% | -13.07% | |
57 Neutral | HK$58.61B | 7.82 | 8.62% | 3.75% | -1.57% | 1.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$721.31M | -5.63 | 476.63% | ― | -17.39% | -45.76% |
* Healthcare Sector Average
HK:1099
Sinopharm Group Co
18.78
1.15
6.50%
HK:0673
China Health Group
0.52
0.41
372.73%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.70
1.47
14.39%
HK:1931
IVD Medical Holding Limited
0.94
-0.81
-46.29%
HK:2192
Medlive Technology Co., Ltd.
8.66
-3.17
-26.80%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.82
-1.44
-19.83%
Sinopharm Group Co Corporate Events
Sinopharm Medical Device Unit Sees Profit Decline Amid Modest Revenue Growth
Apr 23, 2026
Sinopharm subsidiary China National Medical Device Co. Ltd. reported modest top-line growth for the three months ended 31 March 2026, with revenue rising 1.23% year on year to RMB 16.999 billion and total assets up 3.82%. However, operating profit...
Sinopharm subsidiary posts steady Q1 profit growth but cash flow weakens
Apr 22, 2026
Sinopharm Group has disclosed key unaudited first-quarter figures for its Shanghai-listed subsidiary China National Medicines Corporation, showing steady year-on-year revenue growth and modest improvement in profitability. Revenue for the three mo...
Sinopharm Accord Q1 2026 Preliminary Results Show Profit Decline Amid Stable Asset Base
Apr 21, 2026
Sinopharm Group has released preliminary unaudited first-quarter 2026 figures for its Shenzhen-listed subsidiary Sinopharm Accord, showing a slight contraction in top-line performance alongside softer profitability metrics. The update offers inves...
Sinopharm Sets April Board Meeting to Approve First-Quarter 2026 Results
Apr 10, 2026
Sinopharm Group has scheduled a board meeting for April 24, 2026, to review and approve the unaudited quarterly results for the three months ended March 31, 2026. The announcement signals the forthcoming release of key financial data that will off...
Sinopharm Subsidiary Sinopharm Accord Posts Sharp 2025 Profit Rebound Despite Weaker Cash Flow
Apr 1, 2026
Sinopharm Group has disclosed the 2025 audited financial results of its Shenzhen-listed subsidiary, Sinopharm Accord, highlighting its position in the Chinese pharmaceutical distribution and healthcare sector. The company reported modest asset and...
Sinopharm Defies Industry Headwinds With 2025 Profit Growth and Retail Turnaround
Mar 22, 2026
Sinopharm reported its annual results for 2025, highlighting that despite a challenging macro-environment and restructuring in the pharmaceutical distribution industry, the group achieved a year-on-year net profit increase of 3.94 percent. Managem...
Sinopharm Proposes Final Cash Dividend of RMB 0.69 per Share for 2025
Mar 22, 2026
Sinopharm Group Co. Ltd., a leading pharmaceutical distributor and healthcare services provider in China, has announced a proposed final cash dividend of RMB 0.69 per share for the financial year ended 31 December 2025. The dividend, to be paid in...
Sinopharm Subsidiary Posts 2025 Revenue Growth Amid Flat Earnings and Stronger Cash Flow
Mar 19, 2026
Sinopharm Group has disclosed the 2025 audited financial results of its Shanghai-listed subsidiary China National Medicines Corporation, showing modest top-line growth but largely flat profitability. Revenue rose 3.7% year on year to RMB 52.47 bil...
Sinopharm Device Subsidiary Boosts Profit and Cash Flow Despite Lower 2025 Revenue
Mar 19, 2026
Sinopharm Group disclosed the 2025 audited financial results of its medical device subsidiary CNMDC, showing revenue of RMB 74.89 billion, down 2.35% year on year, while operating profit edged up 2.38% to RMB 1.25 billion. Total comprehensive inco...
Sinopharm Accord Posts Strong 2025 Profit Growth Despite Slight Revenue Dip
Mar 17, 2026
Sinopharm Group has released preliminary 2025 financial data for its Shenzhen-listed subsidiary Sinopharm Accord, showing a slight 1.29% decline in revenue to RMB 73.42 billion but a significant improvement in profitability. Operating profit jumpe...
Sinopharm Sets March Board Meeting to Approve 2025 Annual Results
Mar 10, 2026
Sinopharm Group has scheduled a board meeting for 20 March 2026 to review and approve the consolidated annual results for the year ended 31 December 2025. The board will also consider the declaration of any dividends, a decision that could influen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.